Bausch Health announces good Phase III results from psoriasis therapy

Bausch Health–formerly known as Valeant–yesterday reported on a press release that the Journal of Drugs in Dermatology has published results from as many as two Phase III clinical trials, assessing corticosteroid Bryhali (halobetasol propionate) Lotion, 0.01% in patients with psoriasis.